Antithrombin Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Antithrombin is a serine protease inhibitor that plays a central role in regulating blood coagulation, and commercial products derived from human plasma or recombinant sources are administered primarily to patients with hereditary or acquired antithrombin deficiency. The market generated roughly USD 0.74 billion in revenue in 2025 and is forecast to expand at a compound annual growth rate near 5.0% through the end of the decade. Demand is concentrated in hospital and specialty care settings, where the protein is used in therapeutic, diagnostic, and research applications.

• •Estimated 2025 market value: approximately USD 0.74 billion.
• •Forecast CAGR: roughly 5.0% through the late 2020s and into the 2030s.
• •Forecast range for the early-to-mid 2030s: USD 0.82 billion to nearly USD 1.0 billion depending on source and horizon.

Rising rates of diagnosis for hereditary antithrombin deficiency and growing clinical adoption in critical care are expanding the addressable patient pool. Broader use in high-acuity settings such as ECMO, cardiac surgery, sepsis, and COVID-19-related coagulopathies has reinforced demand, while improvements in plasma fractionation capacity and the introduction of recombinant alternatives are helping to stabilize supply. Aging populations in developed markets and improving access to advanced therapies in emerging economies are further supporting volume growth.

• •Increased screening and diagnosis of inherited antithrombin deficiency.
• •Expanding therapeutic use in ECMO, cardiac surgery, sepsis, and obstetric complications.
• •Growing demand for recombinant products that lessen dependence on human plasma supply.

The market is commonly segmented by usage (therapeutics, diagnostics, research, and others) and by source, with human plasma-derived antithrombin currently dominant and recombinant products representing a growing niche. Therapeutic applications account for the majority share, reflecting direct clinical use, while diagnostic and research demand contribute smaller but stable revenue streams. North America and Europe lead consumption owing to established plasma fractionation infrastructure, reimbursement coverage, and high surgical volumes, while Asia-Pacific is the fastest-growing region as healthcare access and critical care capacity expand.

• •By usage: therapeutics account for the largest share, followed by diagnostics, research, and other applications.
• •By source: human plasma-derived products dominate; recombinant antithrombin from sources such as transgenic goat milk is an emerging segment.
• •By region: North America and Europe are the largest markets; Asia-Pacific is the fastest-growing geography.

What are the recent trends and outlook?

The medium-term outlook is shaped by the transition from plasma-derived to recombinant antithrombin, which offers a more secure supply chain and reduced pathogen risk. Pipeline activity is focused on recombinant candidates suitable for routine prophylactic and critical care use, and on label expansions into new indications such as obstetric complications and trauma-induced coagulopathy. Overall, the market is expected to maintain steady mid-single-digit growth, with recombinant products gradually capturing share from plasma-derived offerings through the early 2030s.

• •Recombinant antithrombin production is moving from niche to mainstream over the forecast horizon.
• •Label expansion into obstetric, trauma, and sepsis-related indications is broadening clinical use.
• •Supply diversification away from a plasma-only model is expected to improve resilience and support predictable mid-single-digit annual growth.